Literature DB >> 18838709

Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.

Sarah A McLaughlin1, Mary J Wright, Katherine T Morris, Gladys L Giron, Michelle R Sampson, Julia P Brockway, Karen E Hurley, Elyn R Riedel, Kimberly J Van Zee.   

Abstract

PURPOSE: Sentinel lymph node biopsy was adopted for the staging of the axilla with the assumption that it would reduce the risk of lymphedema in women with breast cancer. The aim of this study was to determine the long-term prevalence of lymphedema after SLN biopsy (SLNB) alone and after SLNB followed by axillary lymph node dissection (SLNB/ALND). PATIENTS AND METHODS: At median follow-up of 5 years, lymphedema was assessed in 936 women with clinically node-negative breast cancer who underwent SLNB alone or SLNB/ALND. Standardized ipsilateral and contralateral measurements at baseline and follow-up were used to determine change in ipsilateral upper extremity circumference and to control for baseline asymmetry and weight change. Associations between lymphedema and potential risk factors were examined.
RESULTS: Of the 936 women, 600 women (64%) underwent SLNB alone and 336 women (36%) underwent SLNB/ALND. Patients having SLNB alone were older than those having SLNB/ALND (56 v 52 years; P < .0001). Baseline body mass index (BMI) was similar in both groups. Arm circumference measurements documented lymphedema in 5% of SLNB alone patients, compared with 16% of SLNB/ALND patients (P < .0001). Risk factors associated with measured lymphedema were greater body weight (P < .0001), higher BMI (P < .0001), and infection (P < .0001) or injury (P = .02) in the ipsilateral arm since surgery.
CONCLUSION: When compared with SLNB/ALND, SLNB alone results in a significantly lower rate of lymphedema 5 years postoperatively. However, even after SLNB alone, there remains a clinically relevant risk of lymphedema. Higher body weight, infection, and injury are significant risk factors for developing lymphedema.

Entities:  

Mesh:

Year:  2008        PMID: 18838709      PMCID: PMC2652091          DOI: 10.1200/JCO.2008.16.3725

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  23 in total

1.  Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation.

Authors:  Anton Haid; Roswitha Köberle-Wührer; Michael Knauer; Judit Burtscher; Heinz Fritzsche; William Peschina; Zerina Jasarevic; Maria Ammann; Klaus Hergan; Heinz Sturn; Gerhard Zimmermann
Journal:  Breast Cancer Res Treat       Date:  2002-05       Impact factor: 4.872

2.  Sentinel lymph node biopsy lowers the rate of lymphedema when compared with standard axillary lymph node dissection.

Authors:  Mehra Golshan; W Jason Martin; Kambiz Dowlatshahi
Journal:  Am Surg       Date:  2003-03       Impact factor: 0.688

3.  Arm edema in conservatively managed breast cancer: obesity is a major predictive factor.

Authors:  R S Werner; B McCormick; J Petrek; L Cox; C Cirrincione; J R Gray; J Yahalom
Journal:  Radiology       Date:  1991-07       Impact factor: 11.105

4.  Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis.

Authors:  J A Petrek; R T Senie; M Peters; P P Rosen
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

5.  Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer.

Authors:  A Haid; T Kuehn; P Konstantiniuk; R Köberle-Wührer; M Knauer; R Kreienberg; G Zimmermann
Journal:  Eur J Surg Oncol       Date:  2002-11       Impact factor: 4.424

6.  Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients.

Authors:  Igor Langer; Ulrich Guller; Gilles Berclaz; Ossi R Koechli; Gabriel Schaer; Mathias K Fehr; Thomas Hess; Daniel Oertli; Lucio Bronz; Beate Schnarwyler; Edward Wight; Urs Uehlinger; Eduard Infanger; Daniel Burger; Markus Zuber
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

7.  Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer.

Authors:  William E Burak; Scott T Hollenbeck; Emmanuel E Zervos; Karen L Hock; Lisa C Kemp; Donn C Young
Journal:  Am J Surg       Date:  2002-01       Impact factor: 2.565

8.  Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer.

Authors:  J S Rietman; P U Dijkstra; J H B Geertzen; P Baas; J de Vries; W V Dolsma; J W Groothoff; W H Eisma; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2004-10-15       Impact factor: 5.344

9.  Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer.

Authors:  D Kay Blanchard; John H Donohue; Carol Reynolds; Clive S Grant
Journal:  Arch Surg       Date:  2003-05

10.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.

Authors:  Umberto Veronesi; Giovanni Paganelli; Giuseppe Viale; Alberto Luini; Stefano Zurrida; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Chris Robertson; Patrick Maisonneuve; Giuseppe Renne; Concetta De Cicco; Francesca De Lucia; Roberto Gennari
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

View more
  142 in total

1.  Prospective surveillance of breast cancer-related lymphoedema in the first-year post-surgery: feasibility and comparison of screening measures.

Authors:  J M Blaney; G McCollum; J Lorimer; J Bradley; R Kennedy; J P Rankin
Journal:  Support Care Cancer       Date:  2014-11-16       Impact factor: 3.603

Review 2.  The lymphatic vasculature in disease.

Authors:  Kari Alitalo
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

3.  Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study.

Authors:  Marilyn L Kwan; Jeanne Darbinian; Kathryn H Schmitz; Rebecca Citron; Paula Partee; Susan E Kutner; Lawrence H Kushi
Journal:  Arch Surg       Date:  2010-11

4.  Use of sentinel lymph node biopsy to select patients for local-regional therapy after neoadjuvant chemotherapy.

Authors:  Lillian M Erdahl; Judy C Boughey
Journal:  Curr Breast Cancer Rep       Date:  2014-03

5.  Regulation of inflammation and fibrosis by macrophages in lymphedema.

Authors:  Swapna Ghanta; Daniel A Cuzzone; Jeremy S Torrisi; Nicholas J Albano; Walter J Joseph; Ira L Savetsky; Jason C Gardenier; David Chang; Jamie C Zampell; Babak J Mehrara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

6.  Assessing patterns of practice of sentinel lymph node biopsy for breast cancer in Latin America.

Authors:  Sergio A Acuna; Fernando A Angarita; Jaime Escallon
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

7.  Obesity increases inflammation and impairs lymphatic function in a mouse model of lymphedema.

Authors:  Ira L Savetsky; Jeremy S Torrisi; Daniel A Cuzzone; Swapna Ghanta; Nicholas J Albano; Jason C Gardenier; Walter J Joseph; Babak J Mehrara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-23       Impact factor: 4.733

8.  Prevention of Postsurgical Lymphedema by 9-cis Retinoic Acid.

Authors:  Athanasios Bramos; David Perrault; Sara Yang; Eunson Jung; Young Kwon Hong; Alex K Wong
Journal:  Ann Surg       Date:  2016-08       Impact factor: 12.969

9.  Proactive approach to lymphedema risk reduction: a prospective study.

Authors:  Mei R Fu; Deborah Axelrod; Amber A Guth; Francis Cartwright; Zeyuan Qiu; Judith D Goldberg; June Kim; Joan Scagliola; Robin Kleinman; Judith Haber
Journal:  Ann Surg Oncol       Date:  2014-05-09       Impact factor: 5.344

10.  CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy.

Authors:  Rachel L Mintz; Madeleine A Gao; Kahmun Lo; Yeh-Hsing Lao; Mingqiang Li; Kam W Leong
Journal:  Adv Biosyst       Date:  2018-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.